Insights into in the metabolome of the cyanobacterium Leibleinia gracilis from the lagoon of Tahiti and first inspection of its variability

Hiren Solanki¹, Manon Pierdet², Olivier P. Thomas^{1,*}, and Mayalen Zubia^{2,*}

 ¹ Marine Biodiscovery, School of Chemistry and Ryan Institute, National University of Ireland Galway, University Road, H91 TK33 Galway, Ireland
² UMR Ecosystèmes Insulaires Océaniens, LabEx CORAIL, University of French Polynesia, Faa'a, BP6570, 98702 Tahiti, French Polynesia

P2 Figure S1. Analytical HPLC chromatograms of the F2 fraction of *L. gracilis* on C18 reverse phase (UV at 210 nm and ELSD)

Figure S2. UHPLC-HRMS chromatogram and MS/MS fragmentation of the isolated major (9*E*)-11oxopalmitoleic acid

P3 Figure S3. ¹H NMR of (9*E*)-11-oxopalmitoleic acid in CD₃OD (600 MHz)

Figure S4. ¹³C NMR spectrum of (9*E*)-11-oxopalmitoleic acid in CD₃OD (150 MHz)

P4 Figure S5. COSY spectrum of (9*E*)-11-oxopalmitoleic acid in CD3OD (600 MHz)

Figure S6. HSQC NMR of (9E)-11-oxopalmitoleic acid in CD3OD (600 MHz)

P5 Figure S7. HMBC NMR of (9*E*)-11-oxopalmitoleic acid in CD3OD (600 MHz)

P6 Figure S8. UHPLC-HRMS chromatogram showing the MS/MS fragmentation spectrum of the main annotated compound Erucamide (m/z 338.3449)

Figure S9. MS/MS fragmentation of the Erucamide: confirmation matching with Metlin database



Figure S1. Analytical HPLC chromatograms of the F2 fraction of *L. gracilis* on C18 reverse phase (UV at 210 nm and ELSD)



Figure S2. UHPLC-HRMS chromatogram and MS/MS fragmentation of the isolated major (9*E*)-11-oxopalmitoleic acid



Figure S3. ¹H NMR of (9*E*)-11-oxopalmitoleic acid in CD₃OD (600 MHz)



Figure S4. ¹³C NMR spectrum of (9*E*)-11-oxopalmitoleic acid in CD₃OD (150 MHz)



Figure S5. COSY spectrum of (9*E*)-11-oxopalmitoleic acid in CD₃OD (600 MHz)



Figure S6. HSQC NMR of (9E)-11-oxopalmitoleic acid in CD₃OD (600 MHz)



Figure S7. HMBC NMR of (9*E*)-11-oxopalmitoleic acid in CD₃OD (600 MHz)



Figure S8. UHPLC-HRMS chromatogram showing the MS/MS fragmentation spectrum of the main annotated compound Erucamide (m/z 338.3449)



Figure S9. MS/MS fragmentation of the Erucamide: confirmation matching with Metlin database